Format

Send to

Choose Destination
Blood. 2017 May 11;129(19):2693-2701. doi: 10.1182/blood-2016-10-743294. Epub 2017 Mar 7.

Validation of single nucleotide polymorphisms in invasive aspergillosis following hematopoietic cell transplantation.

Author information

1
Department of Medicine, University of Washington, Seattle, WA.
2
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
3
Infectious Disease Service, Department of Medicine, and Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY.
4
Division of Public Health Sciences, and.
5
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; and.
6
Department of Biostatistics, University of Washington, Seattle, WA.

Abstract

Invasive aspergillosis (IA) is a significant cause of morbidity and mortality following allogeneic hematopoietic cell transplantation (HCT). Previous studies have reported an association between IA development and single nucleotide polymorphisms (SNPs), but many SNPs have not been replicated in a separate cohort. The presence of a positive serum galactomannan assay (SGM+) has also been associated with a worse prognosis in patients with IA, and genetic determinants in this subset of patients have not been systematically studied. The study cohort included 2609 HCT recipients and their donor pairs: 483 with proven/probable IA (183 SGM+) and 2126 with no IA by standard criteria. Of 25 SNPs previously published, we analyzed 20 in 14 genes that passed quality control. Samples were genotyped via microarray, and SNPs that could not be genotyped were imputed. The primary aim was to replicate SNPs associated with proven/probable IA at 2 years; secondary goals were to explore the associations using an end point of SGM+ IA or proven/probable IA using a different genetic model or time to IA (3 months vs 2 years) compared with the original study. Two SNPs in 2 genes (PTX3, CLEC7a) were replicated. Thirteen SNPs in 9 genes had an association at P ≤ .05 using the secondary aims (PTX3, CLEC7a, CD209, CXCL10, TLR6, S100B, IFNG, PLG, TNFR1), with hazard ratios ranging from 1.2 to 3.29. Underlying genetic differences can influence development of IA following HCT. Identification of genetic predispositions to IA could have important implications in donor screening, risk stratification of recipients, monitoring, and prophylaxis.

PMID:
28270451
PMCID:
PMC5428460
DOI:
10.1182/blood-2016-10-743294
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center